$MET

Is MetLife Outperforming the Nasdaq?

MetLife (MET) has outperformed the Nasdaq Composite, with shares up 22.5% year-to-date and 32.6% over 52 weeks. The company reported a 15.5% increase in adjusted earnings and 7% revenue growth in Q2 2026. Analysts have a 'Moderate Buy' rating with a mean price target of $106.23.

Original reporting
Published Sep 8, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Is MetLife Outperforming the Nasdaq? — source image
Decision brief

The 30-second read

$METBullishMed
01

Why it matters

Earnings beat could drive short‑term price appreciation and attract new buying interest.

02

Market read

MET's strong earnings contrast with a declining Nasdaq, offering a relative long opportunity.

03

What to watch

Potential exposure to interest‑rate volatility and underwriting cycles.

Relevance 8/10Novelty 8/10Timing: post‑Q2 2026 earnings release

Background

MetLife reported Q2 2026 results with double‑digit earnings growth and raised analyst price targets.

Company-level read

Ticker impact

$METBullishHigh confidence
Context

Q2 2026 earnings released: adjusted earnings up 15.5% to $1.57B, EPS $2.43, premiums up 7% to $13.7B.

Expected impact

Potential further upside toward $106 target.

Evidence & confidence

Revenue and earnings beat, bullish analyst consensus, price target above current price.

Market effects

Life‑insurance sector may see relative strength as MET outperforms Nasdaq.

Positive for U.S. large‑cap insurance stocks.

Highlights resilience of diversified insurers amid broader market weakness.

Counterpoint

Valuation may already price in growth; risk of slowdown in premium growth.

Key entities

  • MetLife, Inc.

    Large‑cap insurer reporting Q2 2026 earnings.

Related articles

$METMedAI 8/10

Ukraine antitrust body clears MetLife's acquisition of Polish PZU unit

Ukraine's Antimonopoly Committee approved PZU's acquisition of MetLife's Ukrainian unit, subject to non-compete clauses. PZU aims to close the deal by early 2027, pending NBU approval. The transaction aligns with PZU's regional expansion strategy. MetLife PJSC leads Ukraine's life insurance market with UAH 1.599 billion in H1 2026 premiums, up 11.4% YoY.

$METMedAI 8/10

MetLife, Inc. is furnishing this Current Report on Form 8-K to disclose preliminary information regarding variable investment income prior to the…

METLIFE INC (MET) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. MetLife, Inc. (the "Company") is furnishing this Current Report on Form 8-K to disclose preliminary information regarding variable investment income prior to the availability of the Company’s quarterly earnings release and quarterly financial s

$METMedAI 8/10

MetLife (MET) Q2 2026 Earnings Call Transcript

MetLife (MET) Q2 2026 earnings call reported adjusted earnings of about $1.6 billion, or $2.43 per share, up 15% year over year. Adjusted premiums, fees and other revenues rose 5% (excluding pension risk transfers). Sales increased 7%, led by international growth. MetLife repurchased about $700 million of shares in the quarter and announced a new $3 billion authorization.

$METMed

MetLife Q2 Earnings Call Highlights

MetLife (NYSE:MET) reported Q2 expense ratio of 12.1%, up from 11.7% a year ago, citing a ~50 bps PineBridge Investments impact. Management said it is on track to beat its 12.1% full-year 2026 target. Group Benefits adjusted earnings rose to $503m, RIS to $377m, and MIM to $57m, with multiple segment margin and sales updates.